Teva, AbbVie Tell 3rd Circ. New Precedent Won't Help Buyers

Teva, AbbVie Tell 3rd Circ. New Precedent Won’t Help Buyers

Time Stamp: February 24, 2023 5:53 PM
Source Node: 1977808
By Craig Clough (February 24, 2023, 10:53 PM EST) — AbbVie and Teva Pharmaceuticals pushed back Thursday after buyers of the cholesterol drug Niaspan asked the Third Circuit to consider one of its 2022 opinions before deciding whether to deny them class certification in a suit accusing the pharma companies of a pay-for-delay deal, saying the opinion actually supports denying certification….

Time Stamp:

More from Law 360